Table 5. Various studies with reported fractionation, treatment time, local control and severe complication.
| Study | N | Fraction size (Gy) | Total dose (Gy) | OTT (days) | Follow up | Local control | Severe complication |
|---|---|---|---|---|---|---|---|
| Mendenhall [9] | 304 (T1–T2) | 2.1–2.25 | 56–67 | NA | 5 | T1-93% T2b-72% |
1.6% |
| Burke [10] | 102 (T1–T2) | 1.67–3.33 | 50–74.4 Median 65 |
49 | 5 | 80%–92% | 2% |
| Le [11] | 398 (T1–T2) | 1.3–2.4 | 46.6–76 | 50 | 5 | 82% | 1.8% |
| Reddy [12] | 114 (T1) | 1.8–2 | 60–70 | 42–60 | 5 | 82% | 1.7% |
| Yu [13] | 126 (T1) | 2.5 2.25 2 |
50 65.25 66 |
26–46 | 10 | 76% 84%(>2Gy) |
Nil |
| Voet [14] | 383 (T1) | 2–3.25 | 60–65 | 22–>40 | 5 | 89% | 1.8%–5.3% |
| Dinshaw [6] | 676 (T1–T2) | 3.33 2.5 2–2.5 |
50 60–62.5 55–60 |
22 | 10 | T1-82% T2-57% |
<1% |
| Lee [15] | 128 (T1–T2) | 2 1.2–1.6 (b.i.d) |
66 Gy 60–74.2 |
NA | 3 | T1-86% T2-68% |
2% |
| Gowda [5] | 200 (T1) | 3.28 2.12 |
52.5 50 |
21–26 | 5 | 93% | <1% |
| Garden [16] | 230 (T2) | 2.06–2.26 2 1.2(b.i.d) |
66–70 32–75 74–80 |
45 | 5 | 72% | 4% |
| Cellai [17] | 831 (T1) | ≤2 >2.4 |
<61 >65 |
<45–>60 | 10 | 83% | 0.7% |
| Yamazaki [4] | 180 (T1) | 2 2.25 |
60–66 56.25–63 |
NA | 5 | 77% (2Gy) 92% (2.25Gy) |
Nil |
| Laskar [18] | 652(T1) | 3.33 3.43 2.5 |
50 55 60 |
NA | 10 | 84% (<3Gy) 86.1% (>3Gy) |
1% |
| Ermis [19] | 132 (T1–T2) | 2.75 | 55 | 28 | 5 | 85.6% | 2.2% |
| Dixon [20] | 112 (T2) | 3.28 | 52.5 | 22 | 5 | 82% | 1.8% |
| JCOG0701 [21] | 370 (T1–T2) | 2.4 2 |
60–64.8 66–70 |
NA | 3 | 89.7% 84.1% |
0.5% 1.1% |
| Salas [22] | 138 | 2.25 2 |
63 70 |
40 51 |
10 | 83.9% 83.7% |
1.5% 1.4% |
| Present study | 329 (T1–T2) | 3.5 | 52.5 | 19 | 5 | 91.9% | 2.1% |
OTT, Overall treatment time